The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies. The main question it aims to evaluate the short, medium and long-term clinical course of patients treated with MWA. Participants will not alter their normal clinical and therapeutic practice, due to the observational nature of the study, and all data regarding microwave treatments will be collected (including demographic data). follow their normal clinical and therapeutic path
Observational, retrospective and prospective, monocentric study. The objective is to evaluate the short, medium and long-term clinical course of patients undergoing microwave ablation (MWA) for small renal tumors and primary and secondary liver neoplasms. Evaluation of clinical efficacy (progression free survival),safety and technical outcome of microwave ablation as well as clinical outcome of the procedure will be evaluated.At the end of the follow-up periods, the data collected will be compared with those available in the literature on MWA, cryoablation (CA), radiofrequency ablation (RFA) and surgical resection.
Study Type
OBSERVATIONAL
Enrollment
500
Thermal ablation
IRCCS Ospedale San Raffaele
Milan, Italy
RECRUITINGLocal Tumor Progression Free Survival
Based on imaging evidence of tumor reccurence at site of ablation (within 5mm of ablation margins)
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Time to Local Progression
Time from ablation to imaging evidence of tumor reccurence at site of ablation (within 5mm of ablation margins)
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Overall Survival (OS)
From date of ablation until death for any cause
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Progression Free Survival (PFS)
From date of ablation until any documented evidence of tumor progression at any site
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Organ specific Progression Free Survival (PFS)
From date of ablation until any documented evidence of tumor progression at the ablated organ (including reccurence at ablation site)
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.